

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on October 5, 2005

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

Examining Group 1635  
Patent Application  
Docket No. USF-T150CX  
Serial No. 09/955,174

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Jane J. Zara  
Art Unit : 1635  
Applicant : William G. Kerr  
Serial No. : 09/955,174  
Filed : September 19, 2001  
Conf. No. : 9411  
For : Control of NK Cell Function and Survival by Modulation of SHIP Activity

MS AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.


This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

Included with this supplemental Information Disclosure Statement are copies of Office Actions issued in two related applications, U.S. serial no. 10/097,101, filed March 14, 2002, and

U.S. serial no. 10/605,452, filed September 30, 2003. As the file wrappers of these related applications are available to the Examiner, unless requested by the Examiner, the applicant will not be submitting subsequent Office Actions from these related applications.

The applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853


Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950  
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (2 pages); copies of references cited therein.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/955,174
Filing Date	September 19, 2001
First Named Inventor	William G. Kerr
Art Unit	1635
Examiner Name	Jane J. Zara
Attorney Docket Number	USF-T150CX

Sheet	1	of	2
-------	---	----	---

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

**FOREIGN PATENT DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	F1	WO 99/32619 A1	07-01-1999	Fire et al.	All	
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	09/955,174
Filing Date	September 19, 2001
First Named Inventor	William G. Kerr
Group Art Unit	1635
Examiner Name	Jane J. Zara
Attorney Docket Number	USF-T150CX

Sheet 2 of 2

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	BONETTA, L. "RNAi: Silencing never sounded better" <i>Nature Methods</i> , 2004, 1(1):79-86.	
	R2	CAPLEN, N.J. <i>et al.</i> "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems" <i>PNAS</i> , 2001, 98(17):9742-9747.	
	R3	ELBASHIR, S. <i>et al.</i> "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells" <i>Nature</i> , 2001, 411:494-498.	
	R4	ELBASHIR, S. <i>et al.</i> "RNA interference is mediated by 21- and 22-nucleotide RNAs" <i>Genes &amp; Development</i> , 2001, 15:188-200.	
	R5	HARBORTH, J. <i>et al.</i> "Identification of essential genes in cultured mammalian cells using small interfering RNAs" <i>J. Cell Sci.</i> , Dec. 2001, 114(Pt. 24):4557-4565.	
	R6	MONTGOMERY, M.K. <i>et al.</i> "RNA as a target of double-stranded RNA-mediated genetic interference in <i>Caenorhabditis elegans</i> " <i>Proc. Natl. Acad. Sci. USA</i> , 1998, 95:15502-15507.	
	R7	TUSCHL, T. <i>et al.</i> "RNA interference and small interfering RNAs" <i>ChemBiochem</i> , 2001, 2(4):239-245.	
	R8	TUSCHL, T. <i>et al.</i> "Targeted mRNA degradation by double-stranded RNA in vitro" <i>Genes &amp; Development</i> , 1999, 13:3191-3197.	
	R9	SVOBODA, P. <i>et al.</i> "Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference" <i>Development</i> , 2000, 127:4147-4156.	
	R10	ZAMORE, P. <i>et al.</i> "RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals" <i>Cell</i> , 2000, 101:25-33.	
	R11	Office Action mailed 08/29/2005 in continuation-in-part U.S. Serial No. 10/097,101, filed March 14, 2002.	
	R12	Office Action mailed 08/09/2005 in U.S. Serial No. 10/605,452, filed September 30, 2003.	
	R13		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.